The prescription felt routine. Another refill. Another month of relief from the burning nerve pain that made ordinary life difficult. Millions of people have taken the same medication without a second thought, trusting that if it was commonly prescribed, it must be well understood. But new research is prompting doctors and patients alike to take a closer look. A widely used medication for chronic pain is now being examined for a possible connection to cognitive decline, raising difficult questions about the balance between managing pain today and protecting brain health in the future. While researchers caution that the findings do not prove the drug causes dementia, the study has reignited debate about one of the most frequently prescribed medications for nerve pain.

Gabapentin was originally developed to help control seizures in people with epilepsy. Over the years, however, its use expanded dramatically as physicians discovered it could also relieve nerve-related pain caused by conditions such as sciatica, diabetic neuropathy, shingles, spinal injuries, and chronic back problems. Because it is not an opioid, gabapentin became an increasingly attractive option during efforts to reduce opioid prescribing, and today millions of prescriptions are written each year around the world.

For many patients, the medication has been life-changing. It can reduce persistent burning, tingling, or stabbing pain that otherwise interferes with sleep, work, and everyday activities. Yet as its popularity has grown, researchers have continued to study its long-term effects beyond pain control.

A recent study from researchers at Case Western Reserve University has drawn particular attention. After analyzing large amounts of health data, the investigators found that adults who received repeated gabapentin prescriptions appeared to have a higher likelihood of later developing dementia or mild cognitive impairment compared with similar individuals who did not receive the medication. According to the analysis, repeated prescriptions were associated with approximately a 29% higher risk of dementia and an even greater increase in the likelihood of mild cognitive impairment.

Those numbers naturally sound alarming. However, researchers emphasize that the study identified an association—not proof that gabapentin itself directly causes dementia.

This distinction is critically important.

People who require gabapentin often have chronic medical conditions that may independently affect brain health. Chronic pain has already been linked to increased stress, poor sleep, depression, reduced physical activity, social isolation, and inflammation—all factors that may contribute to cognitive decline over time. In other words, the people taking gabapentin may already be at greater risk because of the underlying conditions requiring treatment rather than the medication alone.

Scientists refer to this as “correlation versus causation.”

Just because two things occur together does not necessarily mean one causes the other.

Even so, the findings raise important questions that deserve further investigation.

Researchers are now trying to determine whether the medication itself plays any role in cognitive changes, whether certain patients are more vulnerable than others, or whether the increased risk is almost entirely explained by the health conditions being treated.

Doctors point out that gabapentin can already cause temporary side effects in some individuals, including drowsiness, dizziness, slowed thinking, memory difficulties, and problems with concentration. These effects usually improve after adjusting the dose or discontinuing the medication, but they highlight why long-term cognitive health remains an important area of research.

Age may also matter.

Older adults often process medications differently than younger people because of changes in kidney function, metabolism, and sensitivity to certain drugs. Since dementia risk naturally increases with age, researchers are especially interested in understanding whether prolonged gabapentin use affects older patients differently than younger adults.

Despite the recent headlines, medical experts strongly advise patients not to stop taking gabapentin without speaking to their healthcare provider. Suddenly discontinuing the medication can lead to withdrawal symptoms, worsening pain, and, for people using it to control seizures, potentially dangerous complications.

Instead, the study reinforces the importance of regular medication reviews.

Patients taking gabapentin long-term may benefit from discussing several questions with their healthcare provider:

• Is this medication still the best treatment for my condition?
• Am I taking the lowest effective dose?
• Are there non-drug therapies that could reduce my reliance on medication?
• Should my memory or cognitive function be monitored over time?

For some individuals, physical therapy, exercise programs, weight management, improved sleep, counseling, or other pain-management strategies may complement or reduce the need for long-term medication. For others, gabapentin may still offer benefits that clearly outweigh any potential risks.

Researchers also stress that additional studies are needed before firm conclusions can be reached. Future investigations will need to follow patients over longer periods and carefully separate the effects of chronic pain itself from the effects of the medication.

The conversation surrounding gabapentin ultimately reflects a broader challenge in modern medicine. Every treatment involves balancing benefits against potential risks. Pain relief can dramatically improve quality of life, mobility, and mental health, but long-term safety remains an essential part of responsible medical care.

The latest research does not mean gabapentin is unsafe for everyone. Rather, it serves as a reminder that commonly prescribed medications should continue to be studied as new evidence emerges. Patients and healthcare professionals can then make informed decisions together, based on the latest available science and each person’s individual medical needs.

For now, the most important message is one of awareness rather than alarm. Chronic pain deserves effective treatment, but long-term medications should be reviewed periodically, especially as new research expands our understanding of their possible effects. Asking questions, staying informed, and maintaining open communication with a healthcare provider remain the best ways to balance relief today with health in the years ahead.